IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.486
NA - Nord America 3.116
SA - Sud America 1.465
EU - Europa 1.323
Continente sconosciuto - Info sul continente non disponibili 713
AF - Africa 195
OC - Oceania 5
AN - Antartide 1
Totale 12.304
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.948
SG - Singapore 2.728
BR - Brasile 1.161
CN - Cina 928
HK - Hong Kong 594
VN - Vietnam 507
IT - Italia 374
RU - Federazione Russa 228
FR - Francia 221
DE - Germania 211
KR - Corea 181
BD - Bangladesh 142
AR - Argentina 117
IN - India 101
TG - Togo 68
MX - Messico 62
GB - Regno Unito 60
ID - Indonesia 58
EC - Ecuador 57
CA - Canada 56
IQ - Iraq 43
TR - Turchia 38
ZA - Sudafrica 36
CO - Colombia 33
AT - Austria 32
FI - Finlandia 32
PY - Paraguay 28
NL - Olanda 27
CL - Cile 26
PL - Polonia 26
JP - Giappone 23
ES - Italia 22
PK - Pakistan 21
VE - Venezuela 18
UA - Ucraina 16
UZ - Uzbekistan 16
EG - Egitto 15
MA - Marocco 14
TN - Tunisia 14
IE - Irlanda 13
KE - Kenya 13
LT - Lituania 13
JO - Giordania 12
SA - Arabia Saudita 12
PE - Perù 11
UY - Uruguay 11
JM - Giamaica 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
SE - Svezia 9
AZ - Azerbaigian 8
HN - Honduras 7
PT - Portogallo 7
CR - Costa Rica 6
KZ - Kazakistan 6
NP - Nepal 6
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
IL - Israele 5
LB - Libano 5
PH - Filippine 5
ET - Etiopia 4
GR - Grecia 4
GT - Guatemala 4
MD - Moldavia 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
IR - Iran 3
KW - Kuwait 3
NI - Nicaragua 3
OM - Oman 3
QA - Qatar 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AU - Australia 2
BE - Belgio 2
BW - Botswana 2
GP - Guadalupe 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SC - Seychelles 2
TH - Thailandia 2
AD - Andorra 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BM - Bermuda 1
BY - Bielorussia 1
CD - Congo 1
Totale 11.566
Salva come PNG Salva come JPEG
Città #
Singapore 729
Hong Kong 584
Council Bluffs 563
Beijing 384
San Jose 320
Boardman 316
Ashburn 200
Lauterbourg 190
Hefei 183
Ho Chi Minh City 180
Seoul 178
Frankfurt am Main 149
Hanoi 123
Los Angeles 117
Redondo Beach 92
Dallas 91
São Paulo 91
The Dalles 82
Buffalo 79
Lomé 68
Ogden 60
Santa Clara 60
New York 47
Milan 46
Rio de Janeiro 41
Guayaquil 30
Mexico City 29
Rome 29
Nuremberg 28
Belo Horizonte 27
Naples 25
Brasília 24
Helsinki 23
Mumbai 23
Phoenix 23
Porto Alegre 23
Curitiba 21
Biên Hòa 19
Orem 19
Remanzacco 19
Boston 18
Da Nang 18
Ispra 18
Montreal 18
Brooklyn 17
Haiphong 17
Hyderabad 17
Warsaw 17
Chicago 16
Tokyo 16
Vienna 16
Amsterdam 15
Campinas 14
Columbus 14
Johannesburg 14
Ribeirão Preto 14
Salvador 14
Shanghai 14
Atlanta 13
Codroipo 13
Quito 13
Tashkent 13
Baghdad 12
Goiânia 12
Thái Bình 12
Amman 11
Denver 11
Dublin 11
Jakarta 11
Maceió 11
Munich 11
Nairobi 11
Santo André 11
Ankara 10
Duque de Caxias 10
Franca 10
Guangzhou 10
Hải Dương 10
Istanbul 10
Xi'an 10
Asunción 9
Bologna 9
Buenos Aires 9
Cape Town 9
Carapicuíba 9
Fortaleza 9
London 9
Medellín 9
Philadelphia 9
Thái Nguyên 9
Tunis 9
Bắc Giang 8
Cabo Frio 8
Chennai 8
Dhaka 8
Guarulhos 8
Houston 8
Las Vegas 8
Manaus 8
Miami 8
Totale 6.039
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 189
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 166
The uropathologist of the future: getting ready with intelligence for the prostate cancer tsunami 117
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 116
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care 113
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 109
A gender-related dichotomy in bladder cancer 104
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review 99
Giant cell carcinoma of the urinary bladder: Clinicopathologic analysis and oncological outcomes 98
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 90
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease 88
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 88
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 84
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 83
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 81
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 80
Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer 80
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 80
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 76
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature 75
Patients ask and pathologists answer: ten questions around prostate cancer grading 74
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 74
Agent-Based Learning Model for the Obesity Paradox in RCC 74
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 73
An update on investigational therapies that target STAT3 for the treatment of cancer 73
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 73
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 72
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 71
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 71
Epigenetic modulations and lineage plasticity in advanced prostate cancer 71
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population 71
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 70
Treating prostate cancer by antibody-drug conjugates 69
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 69
Histopathology of Prostate Cancer and its Precursors 69
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 68
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 68
Are liver nested stromal epithelial tumors always low aggressive? 67
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 67
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 66
Targeted treatment of renal cell carcinoma 66
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 66
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 64
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 63
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 62
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 62
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 61
Designing novel immunocombinations in metastatic renal cell carcinoma 61
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 61
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 61
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 61
An update on immunotherapy in uro-oncology 61
Bone targeting agents in patients with metastatic prostate cancer: State of the art 61
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis 61
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 60
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 60
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 60
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 60
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 59
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 59
Staging and reporting of renal cell carcinomas 59
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 59
Epigenetic modifications and modulators in prostate cancer 59
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 59
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 59
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 58
The most effective but largely ignored target for prostate cancer early detection and intervention 58
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 58
Emerging Molecular Technologies in Genitourinary Tumors 56
Pathology without microscope: From a projection screen to a virtual slide 56
Renal Cell Carcinoma: genomic landscape and clinical implications 56
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 56
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 56
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 56
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 56
Digital and computational transition in the pathology lab: when did it start? 56
T1 bladder carcinoma with variant histology: pathological features and clinical significance 56
OUTCOMES OF DIFFERENT PATTERN OF SEMINAL VESICLE INVASION IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY 55
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 55
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 55
Editorial: Emerging biomarkers in genitourinary tumors 55
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 54
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 54
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis 54
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 54
Quick steps toward precision medicine in renal cell carcinoma 54
Molecular classification of bladder urothelial carcinoma using nanostring‐based gene expression analysis 54
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 54
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 53
Prostate cancer pathology: What has changed in the last 5 years 53
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate 53
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 53
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 53
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 53
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 52
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 52
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 52
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 52
Oncocytic Tumors in the Kidney: A Trifocal Review - Integrated Pathological, Cytopathological, and Molecular Perspectives (Part 1) 51
Morphologic spectrum of the epithelial tumors of the male and female urethra 51
Totale 6.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024411 25 9 17 10 36 24 10 22 88 112 29 29
2024/20253.489 74 226 38 51 63 162 97 106 341 449 584 1.298
2025/20267.245 502 740 1.030 924 807 625 604 292 258 441 687 335
2026/2027531 176 355 0 0 0 0 0 0 0 0 0 0
Totale 12.304